The treatment is the first short-duration facial injectable available in the region for the temporary improvement of lines between the eyebrows.
Allergan Aesthetics, an AbbVie company, announced that the European Commission has approved Boey (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. The approval applies to all 30 countries within the European Economic Area.
Boey is the first rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe, according to a press release from AbbVie. In clinical studies, the onset of effect was observed as early as eight hours after treatment, and the effects typically lasted for two to three weeks. The product previously received approval in Canada in June 2026.
“The EU approval of Boey marks an important step forward for our development program and builds on the momentum we’ve established with Health Canada’s approval earlier this year,” says Darin Messina, PhD, senior vice president of aesthetics research and development at AbbVie, in a release. “This milestone reflects the scientific rigor behind Boey and reinforces our commitment to advancing innovative options as we work to bring this first-of-its-kind treatment to healthcare professionals and consumers around the world.”
The introduction of the treatment follows research into patient preferences regarding aesthetic procedures. An Allergan Aesthetics survey found that 80% of people are open to learning about new treatments, and 79% wish they could temporarily preview the results of a treatment before committing to long-lasting outcomes, according to the company. Boey was developed to provide an option for patients who are curious about injectables but hesitant about long-term results.
Boey was developed by the makers of Botox Cosmetic, which is marketed as Vistabel or Vistabex in the European Union. According to Allergan Aesthetics, Botox Cosmetic is the only neurotoxin that has been clinically tested for safety following treatment with Boey.
The company is currently preparing to launch Boey across Europe and will provide healthcare professionals with education and training regarding its use.
ID 40125956 © Monkey Business Images | Dreamstime.com
